Aldumastat

Galapagos CEO Paul Stoffels to Step Down as Company Splits into Two Entities

a month ago

• Paul Stoffels will retire as Galapagos CEO within 12 months after three years at the helm, during which he transformed the company's focus to cell therapy and oncology through strategic acquisitions. • Galapagos is separating into two entities: the original company will retain cell therapy assets while a new spin-off company (SpinCo) will control €2.45 billion ($2.8 billion) in cash from the Gilead partnership. • Henry Gosebruch, former Neumora CEO with extensive M&A experience, has been appointed to lead SpinCo with a mandate to build a pipeline through acquisitions of assets with proven proof-of-concept data.

Galapagos CEO Paul Stoffels to Step Down as Company Splits into Two Entities

Drug Development Updates